MedCity News October 24, 2024
Radiant Biotherapeutics’ Multabodies are antibodies engineered to offer better binding strength to their targets. The preclinical startup’s lead program goes after a cancer immunotherapy target being pursued by several biotech companies already in early clinical development.
An antibody drug is only as good as its ability to connect to its target. Sometimes a mutation at the binding point enables the target to escape, says Art Fratamico, CEO of startup Radiant Biotherapeutics. In other cases, the antibody might just fall off. Either way, without a strong connection to its target, a drug does not work.
Radiant’s technology imbues an antibody with more chances to bind to its target and maintain a connection. The startup is preclinical but it already has two...
Today's Sponsors
Today's Sponsor